title: The new ACC/AHA cardiovascular risk guidelines: impact and controversies.
authors.affiliation: Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD. aremaley1@cc.nih.gov.
authors.forename: Alan T
authors.initials: AT
authors.lastname: Remaley
authors.affiliation: Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Shamburek
authors.affiliation: Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD.
authors.forename: Marcelo
authors.initials: M
authors.lastname: Amar
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008511:Medicine; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors